New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

Volume 2, # 6 October 1996

Table of Contents

STATE-OF-THE-ART IN THE MANAGEMENT OF CANCER

BREAST CANCER - PART III

DIAGNOSIS, STAGING, MONITORING AND PROGNOSIS

CURRENT METHODOLOGIES

382

Tumor Differentiation

383

Proliferative Rate 383
Neopharm 383
Tumor Invasiveness or Metastatic Potential 383
Other Breast Cancer Markers 384
Inherited susceptibility 384
Estrogen- and progesterone-receptor proteins 385
p53 385
HER-2/neu (c-erbB-2) 385
Prostate-specific antigen (PSA) 385
Other markers/indicators 385
In vitro TESTING METHODOLOGIES 386
In vitro Diagnostics 386
Biomira Diagnostics 386
Centocor 387
Geron 387
Horus Therapeutics 387
Matritech 387
Novopharm Biotech 387
Oncogene Science 387
Oncor 388
Paracelsian 388
Reference Laboratory Services 388
Impath 388
MRDx Diagnostics 388
In vivo IMAGING APPROACHES 389
Mammography 389
Digital mammography 389
Ultrasound Imaging 389
ATL 389
Mammoscintigraphy/Immunoscintigraphy 389
Antisoma 389
Biomira 389
Immunomedics 390
Targon 390
Magnetic Resonance Imaging (MRI) 390
Fonar 390
Positron Emission Tomography (PET) 390
Optical/Laser Imaging 390
INVASIVE PROCEDURES 391
Biopsy 391
Biopsys Medical 391
United States Surgical 391
Ductoscopy 391
Intra-operative Cancer Detection 392
Neoprobe 392

 

MORE ON PROSTATE CANCER

NOVELTHERAPEUTICS 392
Gene Therapy 392
Axis Genetics 392
Calydon 392
Genome Therapeutics Corporation 394
Genta 394
Ingenex 394
Introgen Therapeutics 394
Immunotherapy 395
Centocor 395
Maxim Pharrnaceuticals 395
Medarex 395
OTHER DEVELOPMENTS 395
Genomics 395
Recommendations/Approvals 395
Hoechst Marion Roussel 395
Immunex 395
Schering-Plough 396

 

MEETING COVERAGE


CaP CURE'S THIRD ANNUAL
SCIENTIFIC RETREAT
INCLINE VILLAGE AT LAKE TAHOE, CA
SEPTEMBER 5-8, 1996

CAP CURE AND THE MEETING 396
PROSTATE CANCER RESEARCH 396
THE GENETICS CONSORTIUM 396
Database of Patient Histories and DNA Samples (PROGRESS) 396
TOOLS EMPLOYED IN PROSTATE CANCER RESEARCH 397
Other Prostate Cancer Databases 397
Animal Models 397
Transgenic Animals 397
THERAPEUTICS 397
Prevention of Tumor Growth by Inhibition of Angiogenesis 397
Activation of Tumor Cell Apoptosis 398
The mitogen-activated protein (MAP) kinase pathway 398
Suramin 398
Retinoids and vitamin D analogs 398
Telomerase 398
5-HETE 398
Inhibition of Tumor Cell Growth by Blocking Growth Factor Receptors 398
Epidermal growth factor receptor (EGFr) 398
Immunotherapy 399
MUC-1 399
Gene-modified tumor cell vaccines 399
T cell response stimulation 399
Combination of immunotherapy and chemotherapy 399
Gene Therapy Approaches 400
Other Therapeutic Approaches 400
DELIVERY OF THERAPEUTICS TO TUMOR TARGETS 400
Targeting Drugs to the Vascular Endothelium 400
Targeted Delivery of Cisplatin 400
PROSTATE CANCER STAGING 401
Biochemical Markers 401
Other in vitro Staging Approaches 401
In vivo Imaging 401
High-resolution magnetic resonance imaging (MRI) 401
Positron emission tomography (PET) 401
Immunoscintigraphy 401
THE ANDROGEN RECEPTOR 401

 

OPPORTUNISTIC INFECTIONS IN CANCER PATIENTS
FROM THE 36TH INTERSCIENCE CONFERENCE ON
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY(ICAAC),
NEW ORLEANS, LA, SEPTEMBER 15-18,1996

BACTERIALVAGINOSIS, CERVICITIS, HUMAN PAPILLOMAVIRUS (HPV) AND CIN 402
OTHER BACTERIALL INFECTIONS 403
Vancomycin-resistant Enterococei (VRE) 404
Emerging Resistance to Staphylococcus Epidermidis 404
Stentotrophomonas maltophilia 405
New Therapeutic Modalities for Opportunistic Bacterial Infections 405
Quinupristin/dalfopristin 405
Cefepime 405
Analysis of Cost-Effective Bacterial Prophylaxis 406
VIRAL INFECTIONS 406
Penciclovir for Cold Sores 406
Ganciclovir for Prevention of Cytomegalovirus(CMV) Disease 406
FUNGAL INFECTIONS 407
Empirical Fluconazole in Febrile Neutropenic Patients 407
Itraconazole for Antifungal Prophylaxis 407
Amphotericin B in Intralipid for Candidemia 407

HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887